Intrinsic value of ChemoCentryx - CCXI

Previous Close

$9.70

  Intrinsic Value

$26.56

stock screener

  Rating & Target

str. buy

+174%

Previous close

$9.70

 
Intrinsic value

$26.56

 
Up/down potential

+174%

 
Rating

str. buy

We calculate the intrinsic value of CCXI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  132
  204
  305
  443
  624
  858
  1,152
  1,513
  1,947
  2,459
  3,053
  3,733
  4,499
  5,353
  6,294
  7,322
  8,434
  9,629
  10,906
  12,261
  13,694
  15,203
  16,787
  18,444
  20,176
  21,981
  23,861
  25,818
  27,852
  29,966
Variable operating expenses, $m
  116
  179
  268
  389
  548
  754
  1,012
  1,328
  1,709
  2,159
  2,681
  3,277
  3,950
  4,700
  5,526
  6,429
  7,405
  8,455
  9,575
  10,765
  12,024
  13,348
  14,739
  16,194
  17,714
  19,300
  20,950
  22,668
  24,454
  26,310
Fixed operating expenses, $m
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  55
  56
  57
  58
  60
  61
  62
  64
  65
  66
  68
  69
  71
  72
  74
  76
  77
  79
  81
  83
Total operating expenses, $m
  160
  224
  314
  436
  596
  803
  1,062
  1,379
  1,761
  2,212
  2,736
  3,333
  4,007
  4,758
  5,586
  6,490
  7,467
  8,519
  9,640
  10,831
  12,092
  13,417
  14,810
  16,266
  17,788
  19,376
  21,027
  22,747
  24,535
  26,393
Operating income, $m
  -28
  -20
  -9
  7
  28
  56
  90
  133
  185
  247
  318
  400
  492
  595
  708
  832
  967
  1,111
  1,265
  1,429
  1,603
  1,785
  1,977
  2,178
  2,387
  2,606
  2,834
  3,071
  3,317
  3,573
EBITDA, $m
  -27
  -20
  -8
  8
  30
  58
  93
  137
  190
  253
  326
  409
  504
  609
  725
  851
  989
  1,136
  1,294
  1,461
  1,638
  1,825
  2,021
  2,226
  2,440
  2,663
  2,896
  3,138
  3,389
  3,651
Interest expense (income), $m
  0
  0
  2
  6
  11
  19
  29
  43
  59
  80
  104
  133
  166
  205
  248
  296
  349
  407
  469
  537
  608
  685
  766
  850
  940
  1,033
  1,131
  1,232
  1,338
  1,448
  1,563
Earnings before tax, $m
  -28
  -22
  -14
  -4
  9
  26
  48
  74
  106
  143
  185
  233
  287
  347
  413
  484
  560
  642
  729
  821
  918
  1,020
  1,127
  1,238
  1,354
  1,475
  1,602
  1,733
  1,869
  2,010
Tax expense, $m
  0
  0
  0
  0
  2
  7
  13
  20
  29
  38
  50
  63
  78
  94
  111
  131
  151
  173
  197
  222
  248
  275
  304
  334
  366
  398
  432
  468
  505
  543
Net income, $m
  -28
  -22
  -14
  -4
  7
  19
  35
  54
  77
  104
  135
  170
  210
  253
  301
  353
  409
  469
  532
  599
  670
  745
  822
  904
  989
  1,077
  1,169
  1,265
  1,364
  1,468

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  153
  236
  353
  513
  723
  995
  1,335
  1,753
  2,256
  2,849
  3,538
  4,325
  5,213
  6,203
  7,294
  8,484
  9,773
  11,158
  12,637
  14,208
  15,868
  17,617
  19,452
  21,372
  23,379
  25,471
  27,649
  29,916
  32,273
  34,723
Adjusted assets (=assets-cash), $m
  153
  236
  353
  513
  723
  995
  1,335
  1,753
  2,256
  2,849
  3,538
  4,325
  5,213
  6,203
  7,294
  8,484
  9,773
  11,158
  12,637
  14,208
  15,868
  17,617
  19,452
  21,372
  23,379
  25,471
  27,649
  29,916
  32,273
  34,723
Revenue / Adjusted assets
  0.863
  0.864
  0.864
  0.864
  0.863
  0.862
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
  0.863
Average production assets, $m
  2
  3
  4
  6
  8
  11
  15
  20
  25
  32
  40
  49
  58
  70
  82
  95
  110
  125
  142
  159
  178
  198
  218
  240
  262
  286
  310
  336
  362
  390
Working capital, $m
  32
  49
  73
  106
  149
  205
  275
  362
  465
  588
  730
  892
  1,075
  1,279
  1,504
  1,750
  2,016
  2,301
  2,606
  2,930
  3,273
  3,634
  4,012
  4,408
  4,822
  5,254
  5,703
  6,170
  6,657
  7,162
Total debt, $m
  32
  107
  213
  356
  546
  790
  1,096
  1,472
  1,925
  2,459
  3,079
  3,787
  4,587
  5,477
  6,459
  7,530
  8,690
  9,937
  11,268
  12,682
  14,176
  15,750
  17,401
  19,130
  20,935
  22,818
  24,779
  26,819
  28,940
  31,145
Total liabilities, $m
  138
  213
  318
  461
  651
  895
  1,201
  1,578
  2,030
  2,564
  3,184
  3,893
  4,692
  5,583
  6,564
  7,636
  8,796
  10,042
  11,373
  12,787
  14,281
  15,855
  17,506
  19,235
  21,041
  22,924
  24,884
  26,925
  29,046
  31,250
Total equity, $m
  15
  24
  35
  51
  72
  99
  133
  175
  226
  285
  354
  433
  521
  620
  729
  848
  977
  1,116
  1,264
  1,421
  1,587
  1,762
  1,945
  2,137
  2,338
  2,547
  2,765
  2,992
  3,227
  3,472
Total liabilities and equity, $m
  153
  237
  353
  512
  723
  994
  1,334
  1,753
  2,256
  2,849
  3,538
  4,326
  5,213
  6,203
  7,293
  8,484
  9,773
  11,158
  12,637
  14,208
  15,868
  17,617
  19,451
  21,372
  23,379
  25,471
  27,649
  29,917
  32,273
  34,722
Debt-to-equity ratio
  2.110
  4.540
  6.020
  6.940
  7.540
  7.940
  8.210
  8.400
  8.530
  8.630
  8.700
  8.760
  8.800
  8.830
  8.860
  8.880
  8.890
  8.910
  8.920
  8.930
  8.930
  8.940
  8.950
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -28
  -22
  -14
  -4
  7
  19
  35
  54
  77
  104
  135
  170
  210
  253
  301
  353
  409
  469
  532
  599
  670
  745
  822
  904
  989
  1,077
  1,169
  1,265
  1,364
  1,468
Depreciation, amort., depletion, $m
  0
  1
  1
  1
  2
  2
  3
  4
  5
  6
  8
  10
  12
  14
  16
  19
  22
  25
  28
  32
  36
  40
  44
  48
  52
  57
  62
  67
  72
  78
Funds from operations, $m
  -28
  -21
  -14
  -3
  8
  21
  38
  58
  82
  110
  143
  180
  221
  267
  318
  372
  431
  494
  560
  631
  706
  784
  866
  952
  1,041
  1,134
  1,231
  1,332
  1,437
  1,546
Change in working capital, $m
  12
  17
  24
  33
  43
  56
  70
  86
  104
  122
  142
  162
  183
  204
  225
  246
  266
  286
  305
  324
  342
  361
  378
  396
  414
  431
  449
  468
  486
  505
Cash from operations, $m
  -40
  -38
  -38
  -36
  -35
  -35
  -32
  -28
  -21
  -12
  1
  18
  38
  63
  93
  126
  165
  208
  255
  307
  363
  423
  488
  556
  627
  703
  782
  864
  951
  1,040
Maintenance CAPEX, $m
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -12
  -14
  -16
  -19
  -22
  -25
  -28
  -32
  -36
  -40
  -44
  -48
  -52
  -57
  -62
  -67
  -72
New CAPEX, $m
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -23
  -24
  -25
  -26
  -27
Cash from investing activities, $m
  -1
  -1
  -2
  -3
  -3
  -5
  -6
  -8
  -10
  -12
  -14
  -17
  -20
  -23
  -26
  -29
  -33
  -38
  -42
  -46
  -51
  -56
  -61
  -66
  -71
  -75
  -81
  -87
  -93
  -99
Free cash flow, $m
  -40
  -40
  -40
  -39
  -39
  -39
  -38
  -36
  -31
  -24
  -13
  1
  19
  40
  66
  97
  131
  170
  214
  261
  313
  368
  427
  490
  557
  627
  700
  777
  857
  940
Issuance/(repayment) of debt, $m
  28
  75
  105
  143
  190
  244
  306
  376
  452
  534
  620
  709
  799
  891
  982
  1,072
  1,160
  1,247
  1,331
  1,414
  1,494
  1,574
  1,651
  1,729
  1,806
  1,883
  1,961
  2,040
  2,121
  2,205
Issuance/(repurchase) of shares, $m
  58
  30
  26
  20
  15
  8
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  86
  105
  131
  163
  205
  252
  306
  376
  452
  534
  620
  709
  799
  891
  982
  1,072
  1,160
  1,247
  1,331
  1,414
  1,494
  1,574
  1,651
  1,729
  1,806
  1,883
  1,961
  2,040
  2,121
  2,205
Total cash flow (excl. dividends), $m
  46
  65
  92
  125
  165
  213
  268
  340
  421
  510
  607
  710
  818
  931
  1,048
  1,168
  1,291
  1,417
  1,545
  1,675
  1,807
  1,942
  2,079
  2,219
  2,363
  2,510
  2,661
  2,817
  2,978
  3,145
Retained Cash Flow (-), $m
  -58
  -30
  -26
  -20
  -21
  -27
  -34
  -42
  -50
  -59
  -69
  -79
  -89
  -99
  -109
  -119
  -129
  -139
  -148
  -157
  -166
  -175
  -183
  -192
  -201
  -209
  -218
  -227
  -236
  -245
Prev. year cash balance distribution, $m
  94
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  81
  35
  66
  105
  144
  186
  234
  299
  371
  451
  538
  631
  729
  832
  939
  1,049
  1,163
  1,279
  1,397
  1,518
  1,641
  1,767
  1,895
  2,027
  2,162
  2,300
  2,443
  2,590
  2,743
  2,900
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  78
  32
  57
  86
  112
  135
  158
  187
  213
  236
  255
  269
  277
  279
  276
  267
  253
  235
  215
  193
  170
  147
  124
  103
  84
  67
  52
  40
  30
  22
Current shareholders' claim on cash, %
  50.0
  37.7
  31.8
  29.0
  27.7
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2
  27.2

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

FINANCIAL RATIOS  of  ChemoCentryx (CCXI)

Valuation Ratios
P/E Ratio -11.7
Price to Sales 38.8
Price to Book 9.3
Price to Tangible Book
Price to Cash Flow 12
Price to Free Cash Flow 12
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -34.2%
Ret/ On Assets - 3 Yr. Avg. -39.1%
Return On Total Capital -65%
Ret/ On T. Cap. - 3 Yr. Avg. -51.2%
Return On Equity -65%
Return On Equity - 3 Yr. Avg. -51.2%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -333.3%
EBITDA Margin - 3 Yr. Avg. -111.1%
Operating Margin -341.7%
Oper. Margin - 3 Yr. Avg. -113.9%
Pre-Tax Margin -333.3%
Pre-Tax Margin - 3 Yr. Avg. -111.1%
Net Profit Margin -333.3%
Net Profit Margin - 3 Yr. Avg. -111.1%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CCXI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CCXI stock intrinsic value calculation we used $82.497 million for the last fiscal year's total revenue generated by ChemoCentryx. The default revenue input number comes from 0001 income statement of ChemoCentryx. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CCXI stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CCXI is calculated based on our internal credit rating of ChemoCentryx, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of ChemoCentryx.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CCXI stock the variable cost ratio is equal to 87.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $43 million in the base year in the intrinsic value calculation for CCXI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for ChemoCentryx.

Corporate tax rate of 27% is the nominal tax rate for ChemoCentryx. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CCXI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CCXI are equal to 1.3%.

Life of production assets of 2.5 years is the average useful life of capital assets used in ChemoCentryx operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CCXI is equal to 23.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $79.267 million for ChemoCentryx - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 49.15 million for ChemoCentryx is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of ChemoCentryx at the current share price and the inputted number of shares is $0.5 billion.

RELATED COMPANIES Price Int.Val. Rating
ABBV AbbVie 90.14 174.70  str.buy
BIIB Biogen 321.72 402.94  hold
PFE Pfizer 43.21 34.10  hold
INCY Incyte 65.03 161.51  str.buy
JNJ Johnson&Johnso 144.50 176.79  buy
MRK Merck&Co 74.84 33.05  str.sell
BMY Bristol-Myers 53.27 71.64  hold
AMGN Amgen 192.45 130.16  sell

COMPANY NEWS

▶ ChemoCentryx: 3Q Earnings Snapshot   [05:58PM  Associated Press]
▶ After-hours buzz: BBBY, KRP & more   [Sep-26-18 06:28PM  CNBC]
▶ ChemoCentryx: 2Q Earnings Snapshot   [05:55PM  Associated Press]
▶ 4 Top-Ranked Nasdaq Stocks That Have Doubled This Year   [Jun-14-18 01:15PM  InvestorPlace]
▶ Better Know Biotech: 2 Stocks You Ought to Know About   [May-16-18 08:00AM  Motley Fool]
▶ ChemoCentryx: 1Q Earnings Snapshot   [May-09-18 07:28PM  Associated Press]
▶ ChemoCentryx Inc (NASDAQ:CCXI): When Will It Breakeven?   [Mar-09-18 11:22AM  Simply Wall St.]
▶ ChemoCentryx posts 4Q profit   [07:41AM  Associated Press]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Jan-06-18 10:34AM  Motley Fool]
▶ Here's Why ChemoCentryx Rose as Much as 53.5% Today   [Jan-04-18 12:11PM  Motley Fool]
▶ Should You Buy ChemoCentryx Inc (CCXI) Now?   [Nov-27-17 05:30PM  Simply Wall St.]
▶ ChemoCentryx reports 3Q loss   [Nov-07-17 05:49PM  Associated Press]
▶ All You Need To Know About ChemoCentryx Incs (CCXI) Risks   [Oct-02-17 05:27PM  Simply Wall St.]
▶ Is There Now An Opportunity In ChemoCentryx Inc (CCXI)?   [Sep-15-17 08:37PM  Simply Wall St.]
▶ ChemoCentryx reports 2Q loss   [01:07AM  Associated Press]
▶ New Strong Buy Stocks for July 18th   [Jul-18-17 07:29AM  Zacks]
▶ ETFs with exposure to ChemoCentryx, Inc. : June 15, 2017   [Jun-15-17 01:27PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.